In the Media

Merck extends oncology and autoimmunity collaboration with BioMed X

Pharma Times

Merck has extended its existing collaboration with BioMed X, an independent research institute located at the University of Heidelberg in Germany, to continue research in the areas of oncology and autoimmunity.

Merck, BioMed X extend collaboration in oncology, autoimmunity

Merck has extended its collaboration with German company BioMed X and will start six additional research projects at the BioMed X Institute.

BioMedX Extends Collaboration with Merck

BioMed X, an independent biomedical research institute, has extended its ongoing collaboration with Merck.

The BioMedX Institute: a new research model at the interface between industry and academia

Chemicals Knowledge Hub

BioMed X is a new collaborative model between academia and industry developing innovative products in the fields of biomedicine, molecular biology, cell biology and diagnostics.

Studying Depression at a Molecular Level

Psychiatric Times

How do defective neuro-glia interactions contribute to depression? A recent study suggests that alterations in astrocyte metabolism is a major hallmark of depression. In this Mental Health Minute, Michal Slezak, PhD, explains how he and other researchers used state-of-the-art imaging techniques and genetic approaches to identify molecular processes impaired in depression.

Digitization and AI at the Forefront

STARTUPCITY

“In the midst of every crisis, lies great opportunity.” Regarding the most important trends in biomedical research for 2021, this quote by Albert Einstein seems more topical than ever before.

Crossing the Border

the Medicine Maker

How to get macromolecules across the intestinal epithelial barrier

J&J taps BioMed X for crowdsourced oral biologics delivery push

FiercePharma

Johnson & Johnson has teamed up with BioMed X Institute to advance oral delivery of monoclonal antibodies and other biologics. The initiative will support the work of a small team that will work to identify ways to get large molecules across the intestinal epithelial barrier.

BioMed X begins research project for oral therapeutics delivery

manufacturing Chemist

The collaboration with Janssen Research and Development was facilitated by Johnson & Johnson Innovation.

El Instituto BioMed X inicia un nuevo proyecto de investigación sobre administración de fármacos en colaboración con Janssen

FarmaIndustrial

El instituto de investigación independiente alemán BioMed X anuncia su nuevo proyecto de investigación con Janssen Research & Development, una de las compañías farmacéuticas Janssen de Johnson & Johnson, que se esforzará por descubrir nuevos mecanismos de transporte en el tracto intestinal humano que podrían utilizarse para la administración oral de diversas modalidades terapéuticas.

BioMed X, Janssen Enter Oral Drug Delivery Alliance

ContractPharma

Aims to discover novel transport mechanisms which could be utilized for oral delivery of therapeutic modalities.

BioMed X Launches Drug Delivery Research Project with Janssen

BioPharm International

The project is aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.

Crowdsourcing and open innovation in drug discovery: recent contributions and future directions

Drug Discovery Today

The past decade has seen significant growth in the use of ‘crowdsourcing’ and open innovation approaches to engage ‘citizen scientists’ to perform novel scientific research. Here, we quantify and summarize the current state of adoption of open innovation by major pharmaceutical companies.

BioMed X Institute completes first neuroscience research project with Boehringer Ingelheim

SelectScience

Research Team BMP (Brain Microcircuits in Psychiatric Diseases) uncovered alterations in astrocyte metabolism as a major hallmark of depression

Germany-based BioMed X Institute completed its first joint research project in neuroscience with Boehringer Ingelheim.

BioSpace

Following completion of the project, the research has now transitioned to BI for additional development. The team has validated candidate genes in several biological systems, and as a key achievement, proposes novel glial-specific drug targets for therapy of depression.

The Biomed X Institute, of Heidelberg, Germany, said it completed its first joint research neuroscience project with Boehringer Ingelheim GmbH, of Ingelheim, Germany.

BioWorld

The project launched in 2016 to uncover the contribution of astrocytes, a subtype of glial cells, to molecular phenotypes in depression.

Talenten auf der Spur

DER SPIEGEL, special section 'Starkes Land Baden-Württemberg' (print edition for Baden Württemberg)

Careers in the industry: The region around Heidelberg attracts top-class specialists from all over the world with quality of life, a lively international atmosphere and a wide range of jobs in research and industry. (German only)

Biotech in Deutschland – eine Branche weit unter Potenzial

BioSpektrum

Als bedeutender Forschungszweig in der Medizin liefert die Biotechnologie wichtige Impulse für neue Wirkstoffe, Medikamente und Diagnostika. Trotz des großen Innovationspotenzials in Deutsch­ land liegen hier die Investitionen in die Translation von Forschungsergebnissen in marktfähige Produkte weit hinter den internationalen Spitzenstandorten Silicon valley und Boston.

Can AI and Automation Deliver a COVID-19 Antiviral While It Still Matters?

IEEE Spectrum

Researchers are betting that new tools can cut drug discovery from five years to six months

BioMed X Enstitüsü’nden Dr. Ebru Ercan Herbst: Şizofreni her 100 insanda 1’inde görülüyor

Independent Türkçe

From the BioMed X Institute, Dr. Ebru Ercan Herbst: Schizophrenia is seen in 1 in every 100 people. Schizophrenia, which starts between the ages of 16 and 30, causes hallucinations, delusions, and disordered thinking.

Antiviral Drug Discovery Reinvented

GENengnews.com

Despite countless efforts of the global scientific community to mitigate the spread of COVID-19 and its negative consequences for global health and the economy, there is an evident need for new approaches to protect humanity from future pandemics.